NCT00082706View on ClinicalTrials.gov

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 23, 2003

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Bladder CancerUrethral CancerUrachal Cancer
Interventions
DRUG

5-Fluorouracil (5-FU)

Day: 1 - 5 Dose: 200 mg/m2 IVCI daily x 5 days

DRUG

Leucovorin

Day: 1 - 5 Dose:10 mg/m2 daily x 5 days

DRUG

Cisplatin

Day: 1 - 5 Dose: 20 mg/m2 daily x 5 days

DRUG

Gemcitabine

Day: 1 \& 5 Dose: 200 mg/m2 (Two doses only)

Trial Locations (1)

77030-4009

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER